Biodexa Pharmaceuticals (BDRX) FCF Margin (2015 - 2020)

Biodexa Pharmaceuticals has disclosed FCF Margin across 6 years of filings, most recently posting 52.98% for Q4 2020.

• In Q4 2020, FCF Margin rose 4855.0% year-over-year to 52.98%; the TTM figure through Dec 2020 stood at 110.69% (down 10386.0% YoY), while the FY2023 annual figure was 1784.78%, down 78535.0% from the prior year.
• FCF Margin came in at 52.98% for Q4 2020 at Biodexa Pharmaceuticals, roughly flat from 52.98% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 52.98% in Q3 2020 to a low of 138.28% in Q4 2018.
• Average FCF Margin over 5 years is 7.25%, with a median of 35.71% recorded in 2016.
• Year-over-year, FCF Margin jumped 21249 bps in 2016 and plunged 16331 bps in 2018.
• Over 5 years, FCF Margin stood at 46.39% in 2016, then sank by 46 bps to 25.03% in 2017, then slumped by 653 bps to 138.28% in 2018, then jumped by 103 bps to 4.42% in 2019, then surged by 1097 bps to 52.98% in 2020.
• Per Business Quant data, the three most recent FCF Margin figures were 52.98% in Q4 2020, 52.98% in Q3 2020, and 4.42% in Q4 2019.